JP2017533910A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533910A5 JP2017533910A5 JP2017522852A JP2017522852A JP2017533910A5 JP 2017533910 A5 JP2017533910 A5 JP 2017533910A5 JP 2017522852 A JP2017522852 A JP 2017522852A JP 2017522852 A JP2017522852 A JP 2017522852A JP 2017533910 A5 JP2017533910 A5 JP 2017533910A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- polypeptide
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 85
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 46
- 229920001184 polypeptide Polymers 0.000 claims description 45
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 45
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 claims description 34
- 208000007502 anemia Diseases 0.000 claims description 21
- 108010075944 Erythropoietin Receptors Proteins 0.000 claims description 14
- 102100036509 Erythropoietin receptor Human genes 0.000 claims description 14
- 210000003743 erythrocyte Anatomy 0.000 claims description 13
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 12
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 claims description 11
- 239000012190 activator Substances 0.000 claims description 11
- 230000010437 erythropoiesis Effects 0.000 claims description 10
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 8
- 210000001995 reticulocyte Anatomy 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 238000005534 hematocrit Methods 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 208000020832 chronic kidney disease Diseases 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 238000009396 hybridization Methods 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000002903 Thalassemia Diseases 0.000 claims description 2
- 208000005980 beta thalassemia Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 17
- 208000034737 hemoglobinopathy Diseases 0.000 claims 1
- 208000018337 inherited hemoglobinopathy Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 45
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 7
- 102000003951 Erythropoietin Human genes 0.000 description 6
- 108090000394 Erythropoietin Proteins 0.000 description 6
- 229940105423 erythropoietin Drugs 0.000 description 6
- 239000000556 agonist Substances 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 108010019673 Darbepoetin alfa Proteins 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 108700022380 synthetic erythropoiesis Proteins 0.000 description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 2
- 108010074604 Epoetin Alfa Proteins 0.000 description 1
- 102100031939 Erythropoietin Human genes 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229940078467 Prolyl hydroxylase inhibitor Drugs 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229940115115 aranesp Drugs 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 108010084052 continuous erythropoietin receptor activator Proteins 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960003388 epoetin alfa Drugs 0.000 description 1
- 108010002601 epoetin beta Proteins 0.000 description 1
- 229960004579 epoetin beta Drugs 0.000 description 1
- 108010067416 epoetin delta Proteins 0.000 description 1
- 229950002109 epoetin delta Drugs 0.000 description 1
- 108010090921 epoetin omega Proteins 0.000 description 1
- 229950008767 epoetin omega Drugs 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960001046 methoxy polyethylene glycol-epoetin beta Drugs 0.000 description 1
- CSHFHJNMIMPJST-HOTGVXAUSA-N methyl (2s)-2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoate Chemical compound NCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)OC)CC1=CC=CC=C1 CSHFHJNMIMPJST-HOTGVXAUSA-N 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462072889P | 2014-10-30 | 2014-10-30 | |
| US62/072,889 | 2014-10-30 | ||
| PCT/US2015/058116 WO2016069925A1 (en) | 2014-10-30 | 2015-10-29 | Methods and compositions using gdf15 polypeptides for increasing red blood cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020023090A Division JP7154241B2 (ja) | 2014-10-30 | 2020-02-14 | Ｇｄｆ１５ポリペプチドを使用する、赤血球を増加させるための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533910A JP2017533910A (ja) | 2017-11-16 |
| JP2017533910A5 true JP2017533910A5 (enExample) | 2018-12-06 |
| JP6663428B2 JP6663428B2 (ja) | 2020-03-11 |
Family
ID=55858354
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017522852A Expired - Fee Related JP6663428B2 (ja) | 2014-10-30 | 2015-10-29 | Ｇｄｆ１５ポリペプチドを使用する、赤血球を増加させるための方法および組成物 |
| JP2020023090A Active JP7154241B2 (ja) | 2014-10-30 | 2020-02-14 | Ｇｄｆ１５ポリペプチドを使用する、赤血球を増加させるための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020023090A Active JP7154241B2 (ja) | 2014-10-30 | 2020-02-14 | Ｇｄｆ１５ポリペプチドを使用する、赤血球を増加させるための方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10603359B2 (enExample) |
| EP (2) | EP3922259A1 (enExample) |
| JP (2) | JP6663428B2 (enExample) |
| AU (2) | AU2015339134B2 (enExample) |
| CA (1) | CA2964808C (enExample) |
| WO (1) | WO2016069925A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| EP3922259A1 (en) * | 2014-10-30 | 2021-12-15 | Acceleron Pharma Inc. | Methods and compositions using gdf15 polypeptides for increasing red blood cells |
| US11123430B2 (en) | 2015-11-04 | 2021-09-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| CN109414471A (zh) * | 2016-05-24 | 2019-03-01 | 诺和诺德股份有限公司 | Mic-1化合物及其用途 |
| TWI724392B (zh) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| ES3011982T3 (en) | 2018-10-22 | 2025-04-08 | Janssen Sciences Ireland Unlimited Co | Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof |
| WO2021107603A2 (en) * | 2019-11-26 | 2021-06-03 | Yuhan Corporation | Long-acting gdf15 fusion protein and pharmaceutical composition comprising same |
| US12209112B2 (en) * | 2022-09-15 | 2025-01-28 | The Chinese University Of Hong Kong | Methods of preventing or treating diseases, conditions, or disorders associated with chemotherapy |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US4965251A (en) | 1987-04-03 | 1990-10-23 | The Board Of Regents Of The University Of Washington | Pulse treatment of hemoglobinopathies with erythropoietin |
| WO1990008822A1 (en) | 1989-02-03 | 1990-08-09 | Genetics Institute, Inc. | Erythropoietin receptor |
| US5885574A (en) | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| AU5780999A (en) * | 1998-08-21 | 2000-03-14 | Princeton University | Genes that regulate hematopoietic blood forming stem cells and uses thereof |
| EA035911B1 (ru) | 2006-12-18 | 2020-08-31 | Акселерон Фарма Инк. | Применение полипептида, который ингибирует опосредованный активином сигнальный путь, в качестве лекарственного средства |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| DK2340031T3 (da) | 2008-08-14 | 2019-07-15 | Acceleron Pharma Inc | Gdf-fanger til anvendelse ved behandling af anæmi |
| EP2350669B9 (en) * | 2008-10-31 | 2014-06-11 | St Vincent's Hospital Sydney Limited | Methods of prognosis in chronic kidney disease |
| EP3838919A1 (en) * | 2009-08-13 | 2021-06-23 | Acceleron Pharma Inc. | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels |
| AU2012236700B2 (en) * | 2011-03-29 | 2017-06-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of TMPRSS6 gene |
| IN2014MN00949A (enExample) * | 2011-11-22 | 2015-04-24 | Astute Medical Inc | |
| WO2013090635A2 (en) * | 2011-12-14 | 2013-06-20 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
| JP2015506373A (ja) * | 2012-01-26 | 2015-03-02 | アムジエン・インコーポレーテツド | 成長分化因子１５（ｇｄｆ−１５）ポリペプチド |
| EP2644278B1 (en) | 2012-03-27 | 2014-12-10 | Alfa Laval Corporate AB | Centrifugal separator and method of controlling intermittent discharge |
| EP2934584B1 (en) | 2012-12-21 | 2020-02-19 | Aveo Pharmaceuticals, Inc. | Anti-gdf15 antibodies |
| BR112015018104A2 (pt) * | 2013-01-30 | 2017-11-21 | Ngm Biopharmaceuticals Inc | polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições |
| US9161966B2 (en) * | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| PL2981822T3 (pl) * | 2013-05-06 | 2021-07-12 | Scholar Rock, Inc. | Kompozycje i sposoby modulacji czynnika wzrostu |
| CN105658672A (zh) | 2013-08-22 | 2016-06-08 | 阿塞勒隆制药公司 | TGF-β受体II型变体及其用途 |
| EP3119418B1 (en) * | 2014-03-21 | 2022-02-23 | Acceleron Pharma Inc. | Composition for use in a method of treating or preventing anemia by inhibiting activin b and gdf11 |
| CA2952032C (en) * | 2014-06-20 | 2023-03-14 | Aveo Pharmaceuticals, Inc. | Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator |
| EP3922259A1 (en) * | 2014-10-30 | 2021-12-15 | Acceleron Pharma Inc. | Methods and compositions using gdf15 polypeptides for increasing red blood cells |
| TWI621976B (zh) | 2015-07-24 | 2018-04-21 | 瑞鼎科技股份有限公司 | 內嵌式觸控面板驅動方法 |
| EP3423097A4 (en) * | 2016-03-04 | 2019-08-21 | NGM Biopharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR MODULATING BODY WEIGHT |
-
2015
- 2015-10-29 EP EP21170026.5A patent/EP3922259A1/en active Pending
- 2015-10-29 AU AU2015339134A patent/AU2015339134B2/en not_active Ceased
- 2015-10-29 WO PCT/US2015/058116 patent/WO2016069925A1/en not_active Ceased
- 2015-10-29 JP JP2017522852A patent/JP6663428B2/ja not_active Expired - Fee Related
- 2015-10-29 EP EP15854065.8A patent/EP3212213B1/en active Active
- 2015-10-29 CA CA2964808A patent/CA2964808C/en active Active
- 2015-10-29 US US15/523,025 patent/US10603359B2/en active Active
-
2020
- 2020-02-14 JP JP2020023090A patent/JP7154241B2/ja active Active
- 2020-02-28 US US16/804,459 patent/US11642394B2/en active Active
-
2021
- 2021-09-14 AU AU2021232680A patent/AU2021232680A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533910A5 (enExample) | ||
| JP2013501816A5 (enExample) | ||
| Hajishengallis et al. | DEL-1-regulated immune plasticity and inflammatory disorders | |
| RU2012109393A (ru) | Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов | |
| JP2015514115A5 (enExample) | ||
| JP2019194251A5 (enExample) | ||
| JP2017534638A5 (enExample) | ||
| FI3352776T3 (fi) | Htt-repressoreita ja niiden käyttötapoja | |
| JP2012529436A5 (enExample) | ||
| JP2017043632A5 (enExample) | ||
| JP2018525416A5 (enExample) | ||
| JP2016538885A5 (enExample) | ||
| Samuel et al. | Coadministration of adenoviral vascular endothelial growth factor and angiopoietin-1 enhances vascularization and reduces ventricular remodeling in the infarcted myocardium of type 1 diabetic rats | |
| Buccione et al. | Role of interferon regulatory factor 1 in governing T reg depletion, T h1 polarization, inflammasome activation and antitumor efficacy of cyclophosphamide | |
| JP2018527941A5 (enExample) | ||
| RU2016141055A (ru) | Препараты арипипразола, имеющие повышенные скорости впрыска | |
| BR112020013519A2 (pt) | método para tratamento de uma inflamação. | |
| JP2018501791A5 (enExample) | ||
| CA2574531A1 (en) | Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity | |
| JP2018538261A5 (enExample) | ||
| RU2015128078A (ru) | Композиции и способы лечения рака мозга | |
| JP2017523239A5 (enExample) | ||
| IL308645A (en) | Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies | |
| JP6423987B2 (ja) | 制御された遺伝子発現方法 | |
| JP2014530246A5 (enExample) |